Related Experiment Videos
Application of multiple response optimization technique to extended release formulations design.
1Industrial Pharmacy Program, College of Pharmacy, University of Cincinnati, 3223 Eden Avenue, Cincinnati, OH 45267-0004, USA.
Summary
Response surface methodology successfully designed extended-release bumetanide formulations. This approach optimized coating parameters for a preplanned drug release profile, ensuring formulation efficacy.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Formulation Development
Background:
- Designing extended-release (ER) formulations requires precise control over drug release kinetics.
- Optimizing multiple formulation parameters simultaneously presents a significant challenge in pharmaceutical development.
Purpose of the Study:
- To apply response surface methodology (RSM) and multiple response optimization (MRO) for designing ER bumetanide formulations.
- To achieve a preplanned drug release profile through optimized coating formulation parameters.
Main Methods:
- Bumetanide solution was coated onto sugar pellets using a Glatt GPCG 1 Wurster Fluid Bed under a central composite statistical design.
- Release profiles were analyzed at 1, 4, and 8 hours to develop statistical models.
- Superimposed contour diagrams were utilized for MRO to predict optimal coating parameters.
Main Results:
- Statistical models were developed to describe bumetanide release at specific time points.
- Optimized coating formulation parameters were predicted using superimposed contour diagrams.
- The designed ER formulation exhibited a dissolution profile similar to the target profile, confirmed by the similarity factor (F2).
Conclusions:
- RSM and MRO are effective tools for designing and optimizing ER formulations with desired release profiles.
- This methodology enables the development of customized drug delivery systems with predictable pharmacokinetic behavior.
- The study demonstrates a successful application of statistical design in achieving targeted drug release for bumetanide.